Palisade Bio Provides Update on U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions
16. Dezember 2022 08:05 ET
|
Palisade Bio, Inc.
Topline data readout from study expected in first half of 2023 Carlsbad, CA, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company...
Gastroparesis Market Growth Steady at 4.3% CAGR to Reach $6,025.11 Million by 2027: COVID-19 Impact and Global Analysis by The Insight Partners
08. April 2021 07:30 ET
|
The Insight Partners
Pune, India, April 08, 2021 (GLOBE NEWSWIRE) -- According to our new research study on “Gastroparesis Market to 2027 – Global Analysis and Forecast – by Gastroparesis Type, Drug Class Type, and...
Endonovo Therapeutics Provides Corporate Update
26. April 2019 08:00 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, CA, April 26, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic...